Lutathera

Crescent Theranostics

What Is Lutathera?

Lutathera® (lutetium Lu 177 dotatate) is a targeted radioligand therapy approved by the FDA for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). These rare tumors develop in the pancreas and gastrointestinal tract and are often slow-growing but difficult to treat with conventional therapies.

Lutathera combines a tumor-targeting molecule with a radioactive isotope, delivering focused radiation directly to cancer cells—minimizing damage to healthy tissues while effectively reducing tumor growth and symptoms.